BPS News | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.

All posts in BPS News

Meet the 2016 Young Investigator Award Recipient

The Boulder Peptide Society is pleased to announce that Dr. Albert Bowers, at the University of North Carolina, has received the Young Investigator Award for 2016.  The Young Investigator Award was established to support promising peptide scientists during the pre-tenure period. 

Albert Bowers is Assistant Professor in the Division of Chemical Biology & Medicinal Chemistry at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill. Albert received his PhD in organic chemistry (synthetic methods) from the University of Illinois at Chicago under the direction of Dr. David Crich. He carried out postdoctoral research in total synthesis at Colorado State University under the direction of Robert M. Williams, then moved to an NIH sponsored fellowship at Harvard Medical School to continue postdoctoral research in biosynthesis under the direction of Christopher T. Walsh. In addition to his appointment in pharmacy at UNC, Albert is a member of the UNC Lineberger Comprehensive Cancer Center and affiliate member of the Center for Integrative Chemical Biology and Drug Discovery.

Albert Bowers has published 30 manuscripts including 11 in the Journal of the American Chemical Society and 12 since becoming an independent investigator. Albert has received the prestigious Beckman Young Investigator (BYI) Award from the Arnold and Mabel Beckman Foundation. Research in the Bowers lab focuses on chemistry and biotechnology for creating libraries of natural product-like cyclic peptides, in particular by using enzymes from RiPPs (ribosomally translated and posttranslationally modified peptide natural product) pathways. Using an innovative combination of total chemical synthesis, native chemical ligation, and enzymology, his lab was the first to characterize the unique pyridine synthases from the thiopeptide pathways, and answering a long standing question in the biosynthesis of these compounds. Building upon this work, they developed a solid-phase route to thiopeptides with improved activity and solubility. The Bowers lab has also structurally and biochemically characterized a unique E1-like enzyme from the biosynthesis of the pantocin, peptide-derived natural products. By adapting these unique enzymes to various formats of peptide libraries, the Bowers lab aims to develop a combinatorial biosynthesis platform for the discovery of peptide natural product-like inhibitors.

In recognition of his professional and scientific achievements, the Scientific Advisory Board of the Boulder Peptide Society is pleased to present the award to Albert Bowers. Dr. Bowers will present an oral presentation on his research and formally accept the award at the fall Boulder Peptide Symposium Sept 26-29, 2016 in Boulder, Colorado.

2016 Showcase Presenters

Eric Fang
Snapdragon Chemistry, a Cambrex Company

Liquid-phase peptide fragment manufacturing technologies and workflows using batch and flow chemistry

Corey Adams
NoNO Inc.

Clinical Development of a PSD-95 Inhibitor for Acute Ischemic Stroke

Taeju Park
Children's Mercy Kansas City

Rational design of peptides to inhibit protein-protein interactions and block tumor cell migration

Taeju Park
Children's Mercy Kansas City

Rational design of peptides to inhibit protein-protein interactions and block tumor cell migration

Stephanie Seminara
Mass General Brigham

A Kiss to Remember

Alessia Santoprete
IRBM SPA

R2R01: a potent Long-Acting RXFP1 peptide agonist in Phase 2 Development for Cardiovascular and Renal Disorders

Shubhangini Verma
Indian Institute of Technology Guwahati

Injectable and biocompatible hydrogel from amyloidogenic peptide stretch of human tau306–311

Marvin Albers
VU Amsterdam

grabRNA: Smart RNA delivery enables novel therapeutic strategies

Peptide Showcase
Benyi Li
KANSAS UNIV MEDICAL CENTER

An AR protein degrader for prostate cancer therapy

John McGee
Parabilis Medicines

Discovery of FOG-001, a Direct Inhibitor of the β-Catenin/TCF Interaction

Peptide Showcase
Justin Northrup
ThirdLaw Molecular

Macromolecules to Discover Low Nanomolar Binders for TNF-alpha

" ]

Anthony Silvestri
Unnatural Products

Tales of macrocycle medchem: leveraging peptide discovery and optimization technologies

Andre Watson
Ligandal

Peptides for Use in Targeting Payloads

Drug Delivery
Christian Becker
University of Vienna

Targeted innate immune stimulators as therapeutics

Drug Delivery
Katerina Leftheris
Stony Brook University/Vilya, Inc.

Targeting Peptides and Macrocycles as Drugs: Novel approaches on the Horizon

Connor Thomson
Sinopep

Real-world, achievable strategies to improve sustainability in GLP-1 peptide manufacturing (and why it might not matter)

Panel Discussion: Peptides as Radiopharmaceuticals
Murray Wan
Mariana Oncology

Peptide Radiopharmaceutical Panel

Robin Polt
The University of Arizona

Brain Penetrant Glycopeptide Drugs from Endogenous Neuropeptides

Peptide Showcase
Nicolas Gilles
CEA

A snake peptide toxin for treatment of kidney diseases. From bench to bedside

Chemistry of Complex Peptides
Akshay Shah
Pinnacle Medicines

Enablement of Late-Stage Functionalization and High-Throughput Parallel Chemistry for Efficient Peptide Optimization

Chemistry of Complex Peptides
Cesar de la Fuente
University of Pennsylvania

AI for Antibiotic Discovery

Peptides in the Clinic
Kathy Miller
Indiana University

Peptide vaccines for prevention and treatment of cancer

Drug Delivery
Guizhi Zhu
University of Michigan

Engineer and deliver peptide-based proteolysis-targeting vaccines (PROTAX) for cancer immunotherapy

Ross Wang
Temple University

Fluorine-Displacement Reaction (FDR)-mediated Peptide Stapling to Interrogate Protein-Protein Interactions

Jamie Shah
Chem-Impex

Reagents, Relationships, and Resilience: What Family Business Can Teach Us About Peptide Innovation

Chemistry of Complex Peptides
Soren Ostergaard
Novo Nordisk A/S

Half-life extension of peptides using fatty acid derivatization; past, present and future opportunities

Daniela Kalafatovic
University of Rijeka

Using Generative AI to Fast Track Peptide Discovery

AI/Machine Learning with Peptides Workshop
Goran Mausa
University of Rijeka, Faculty of Engineering

AI/Machine Learning Workshop

Drug Delivery
Zhigao Niu
Novo Nordisk

Efforts to improve the SNAC-based formulations for oral peptide delivery

AI/Machine Learning with Peptides Workshop
Nicolai Ree
Gubra

AI/Machine Learning Worshop

Peptide Showcase
Stephane Roche
AdaptBio Therapeutics

ADAPT: An Emerging Platform of Antibody CDR-H3-based Scaffolds for the Discovery of Novel Classes of Protein-Protein Interaction Inhibitors

Lauren Cline
BPS

This is just a test

Chemistry of Complex Peptides
Tom Tucker
Merck and Co., Inc.

Discovery of the Highly Potent and Orally Bioavailable Cyclic Peptide PCSK9 Inhibitor MK-0616

Chemistry of Complex Peptides
Christian Gruber
Medical University of Vienna

Peptide-based approaches to GPCR drug discovery: novel κ-opioid receptor ligands for applications in inflammatory pain

Peptides in the Clinic
Jeff Alberts
Eli Lilly and Company

The Journey of Bioanalytical Support for Peptides from Target of Interest to Post Market

Mandë Holford
Hunter College - CUNY

Killer Snails: Agents of Change and Innovation

Walden Bjørn-Yoshimoto
University of Copenhagen

Somatostatin receptor 4 activating conopeptides inspiring a new class of pain therapeutics

Discounted Early Bird Registration for Peptide Showcase East in Cambridge, MA Ends January 15

Ipsen

The Boulder Peptide Society and Ipsen are pleased to bring you the inaugural Peptide Showcase East in Cambridge, MA, March 14-15, 2016.  In order to get the best price,  Register Now, as Early Bird registration discount ends after January 15, 2016!

The Peptide Showcase will bring together thought leaders in biotech, pharma, and academic institutions to present the most current of paradigms in peptide therapeutics, and to uncover solutions to challenges in peptide drug discovery and development. Peptide Showcase East will be an opportunity for companies to "showcase" new ideas, technologies, and pipeline assets in short business oriented presentations. An electronic partnering forum will be used for pre-arranged one-on-one business meetings between technology providers, licensing partners, and investors. Modeled after the highly successful Peptide Showcase held annually at the Boulder Peptide Symposium, this event, with support from Ipsen, a founding sponsor and world leader in peptide therapeutics, will focus exclusively on innovations in the peptide therapeutics technology space. The event will be held at the Microsoft New England Research and Development Center, located in Kendall Square; Cambridge’s’ iconic innovation district,.

 

About Ipsen

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors.

Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Cambridge, US; Les Ulis, France; Oxford, UK).  Moreover, Ipsen has an active policy of partnerships.

Peptides: long-standing expertise

Ipsen has a long standing expertise, ranging from discovery to delivery of peptides that is being leveraged to create highly differentiated drugs for targets that are not readily addressed by small molecules or antibodies.  Ipsen Bioscience, Ipsen’s new R&D center in Cambridge, which opened in 2014 and was inaugurated on April 1, 2015, develops highly differentiated peptide-based drugs to fulfill unmet medical needs in endocrinology and oncology.

 

2015 Boulder Peptide Symposium Videos Available

Thank you for attending the Boulder Peptide Symposium in September.  We are pleased to announce that videos of the presentations from the Symposium are now available to attendees on our website.  A gallery of photos from the event is also available on the website.  We look forward to seeing you again at a future event.

CLICK HERE FOR VIDEOS

Peptide Showcase East, Cambridge, MA

Ipsen

The Boulder Peptide Society and Ipsen are pleased to bring you the inaugural Peptide Showcase East in Cambridge, MA, March 14-15, 2016.

The Peptide Showcase will bring together thought leaders in biotech, pharma, and academic institutions to present the most current of paradigms in peptide therapeutics, and to uncover solutions to challenges in peptide drug discovery and development. Peptide Showcase East will be an opportunity for companies to "showcase" new ideas, technologies, and pipeline assets in short business oriented presentations. An electronic partnering forum will be used for pre-arranged one-on-one business meetings between technology providers, licensing partners, and investors. Modeled after the highly successful Peptide Showcase held annually at the Boulder Peptide Symposium, this event, with support from Ipsen, a founding sponsor and world leader in peptide therapeutics, will focus exclusively on innovations in the peptide therapeutics technology space. The event will be held at the Microsoft New England Research and Development Center, located in Kendall Square; Cambridge’s’ iconic innovation district,.

Apply to Present or Register early for best pricing!

About Ipsen

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors.

Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Cambridge, US; Les Ulis, France; Oxford, UK).  Moreover, Ipsen has an active policy of partnerships.

Peptides: long-standing expertise

Ipsen has a long standing expertise, ranging from discovery to delivery of peptides that is being leveraged to create highly differentiated drugs for targets that are not readily addressed by small molecules or antibodies.  Ipsen Bioscience, Ipsen’s new R&D center in Cambridge, which opened in 2014 and was inaugurated on April 1, 2015, develops highly differentiated peptide-based drugs to fulfill unmet medical needs in endocrinology and oncology.

 

Inaugural Cambridge Peptide Showcase – March 2016

The Boulder Peptide Society and Ipsen are pleased to bring you the inaugural Peptide Showcase East in Cambridge, MA, March 14-15, 2016. .

The Peptide Showcase will bring together thought leaders in biotech, pharma, and academic institutions to present the most current of paradigms in peptide therapeutics, and to uncover solutions to challenges in peptide drug discovery and development. Peptide Showcase East will be an opportunity for companies to "showcase" new ideas, technologies, and pipeline assets in short business oriented presentations. An electronic partnering forum will be used for pre-arranged one-on-one business meetings between technology providers, licensing partners, and investors. Modeled after the highly successful Peptide Showcase held annually at the Boulder Peptide Symposium, this event, with support from Ipsen, a founding sponsor and world leader in peptide therapeutics, will focus exclusively on innovations in the peptide therapeutics technology space. The event will be held at the Microsoft New England Research and Development Center, located in Kendall Square; Cambridge’s’ iconic innovation district,.

Apply to Present or Register early for best pricing!

About Ipsen

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors.

Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Cambridge, US; Les Ulis, France; Oxford, UK).  Moreover, Ipsen has an active policy of partnerships.

Peptides: long-standing expertise

Ipsen has a long standing expertise, ranging from discovery to delivery of peptides that is being leveraged to create highly differentiated drugs for targets that are not readily addressed by small molecules or antibodies.  Ipsen Bioscience, Ipsen’s new R&D center in Cambridge, which opened in 2014 and was inaugurated on April 1, 2015, develops highly differentiated peptide-based drugs to fulfill unmet medical needs in endocrinology and oncology.

 

Announcing Peptide Showcase East

Ipsen

Boulder, Co (Nov 9) The Boulder Peptide Society and Ipsen are pleased to bring you the inaugural Peptide Showcase East in Cambridge, MA, March 14-15, 2016. .

The Peptide Showcase will bring together thought leaders in biotech, pharma, and academic institutions to present the most current of paradigms in peptide therapeutics, and to uncover solutions to challenges in peptide drug discovery and development. Peptide Showcase East will be an opportunity for companies to "showcase" new ideas, technologies, and pipeline assets in short business oriented presentations. An electronic partnering forum will be used for pre-arranged one-on-one business meetings between technology providers, licensing partners, and investors. Modeled after the highly successful Peptide Showcase held annually at the Boulder Peptide Symposium, this event, with support from Ipsen, a founding sponsor and world leader in peptide therapeutics, will focus exclusively on innovations in the peptide therapeutics technology space. The event will be held at the Microsoft New England Research and Development Center, located in Kendall Square; Cambridge’s’ iconic innovation district,.

Apply to Present or Register early for best pricing!

About Ipsen

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors.

Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Cambridge, US; Les Ulis, France; Oxford, UK).  Moreover, Ipsen has an active policy of partnerships.

Peptides: long-standing expertise

Ipsen has a long standing expertise, ranging from discovery to delivery of peptides that is being leveraged to create highly differentiated drugs for targets that are not readily addressed by small molecules or antibodies.  Ipsen Bioscience, Ipsen’s new R&D center in Cambridge, which opened in 2014 and was inaugurated on April 1, 2015, develops highly differentiated peptide-based drugs to fulfill unmet medical needs in endocrinology and oncology.

 

 

 

 

IU Distinguished Professor Richard DiMarchi elected as a member of National Academy of Medicine

Oct. 19, 2015
FOR IMMEDIATE RELEASE

SOURCE: http://news.indiana.edu/releases/iu/2015/10/dimarchi-national-academy-of-medicine.shtml

BLOOMINGTON, Ind. -- Indiana University Distinguished Professor Richard D. DiMarchi, one of the world's leading peptide chemists, has been elected as a member of the prestigious National Academy of Medicine, becoming the 10th IU faculty member to join the organization and the first on the IU Bloomington campus.

Election to the National Academy of Medicine, previously known as the Institute of Medicine, is considered one of the highest honors in the field of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

An expert in peptide chemistry, biochemistry and pharmacology, DiMarchi also serves as the Linda and Jack Gill Chair in Biomolecular Sciences and the Standiford H. Cox Professor of Chemistry in the IU Bloomington College of Arts and Sciences’ Department of Chemistry, where he previously served as department chair.

DiMarchi’s career spans academia, biotechnology and the pharmaceutical industry. His current research focuses on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization.

"Richard DiMarchi’s rare combination of expertise in both the science and business of drug development has led to new treatments and therapies for diseases, such as diabetes and obesity, that represent some of the leading public health challenges in our state, nation and world," IU President Michael A. McRobbie said. "We are very proud of Richard’s remarkable service to IU's research enterprise and the outstanding contributions he has made to the university’s academic mission and reputation as well as to the larger international scientific community. Indeed, he is highly deserving of this honor, which reflects a thriving 35-year career and groundbreaking work that has led to advancements that continue to touch millions of lives each day."

A highly respected international authority in the discovery, development and manufacture of new drugs, DiMarchi joined IU in 2003 after 22 years as a senior research scientist at Eli Lilly and Co. He discovered Humalog at Lilly Research Laboratories and contributed to the development of a number of peptide and protein-based medicines, including Forteo, rGlucagon and Humulin, which annually sell in excess of $5 billion.

He is the holder of more than 100 patents; co-author of more than 150 scientific papers; co-founder of the IU-initiated Marcadia Biotech, purchased by Roche in 2010, and Calibrium LLC, purchased by Novo-Nordisk in 2015; and co-founder of the biotechnology companies Ambrx, Assembly and MB-2. Merck, Roche and Novo-Nordisk are also independently advancing novel drug candidates inspired by discoveries of the DiMarchi laboratory at IU.

In addition, DiMarchi has been chair of the Peptide Therapeutics Foundation since 2008 and served as a member of the board of directors for the Biotechnology Industry Organization from 2001 to 2003. He has served as scientific advisor to Ferring Pharmaceuticals, Merck, Roche and three venture funds: 5AM Ventures, Thomas McNerney Ventures and Twilight Venture Partners. He is also a member of the external advisory committee for the Industry Collaboration Portal at the IU School of Medicine.

The holder of numerous awards, DiMarchi is the recipient of the 2005 American Association of Pharmaceutical Scientists Career Research Achievement Award in Biotechnology; 2006 American Chemical Society's Barnes Award for Leadership in Chemical Research Management and Esselen Award for Chemistry in the Service of Public Interest; 2007 Carothers Award for Excellence in Polymer Sciences; 2009 Watanabe Award for Life Sciences Research; 2011 Merrifield Award for Career Contributions in Peptide Sciences; 2012 Phillip E. Nelson Innovation Award; and 2014 Erwin Schrödinger-Preis. He is also a 2014 inductee to the National Inventors Hall of Fame and a 2015 inductee to the National Academy of Inventors, and he will receive the 2016 American Chemical Society Alfred Burger Award in Medicinal Chemistry.

New members of the National Academy of Medicine are elected by current active members through a selective process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care and public health.

This year's election includes 70 new members and 10 international members. With the election of the new members, DiMarchi joins a select group of 1,963 active members across the globe.

DiMarchi holds a Ph.D. in biochemistry from IU and a Bachelor of Arts from Florida Atlantic University. He served a postdoctoral fellowship at The Rockefeller University.

Thanks to BPS 2015 Speakers and Attendees

This year's event in Boulder was a great success!  Photos from the event and videos of the presentations will be available on the Boulder Peptide Society webpage soon.

Meet the 2015 Meienhofer Award Recipient
Meet the 2015 Roche Meienhofer Award Recipient: Richard DiMarchi

dimarchiRichard DiMarchi, Ph.D. the Standiford H. Cox Distinguished Professor of Chemistry and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University has been named as the 2015 recipient of the Meienhofer Award for Excellence in Peptide Sciences. Read the announcement.

s2Member®
loading...